The Obesity Drug Pipeline: 10 Questions on Rx Development

Slideshow

Take this quick quiz to test your knowledge of recent advances most likely to have an impact on weight management in your practice.

Treatments for patients with obesity are in development across the pharmaceutical industry, including molecules with novel mechanisms of action that have been evaluated in clinical trials but have not yet received FDA approval.

Take this quick quiz to test your knowledge of the recent advances most likely to have an impact on weight management in your practice.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes / Image credit: ©Argus/AdobeStock

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

Sydney Jennings
December 23rd 2024
Article

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

Patient Care Editorial Staff
December 20th 2024
Article

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

Sydney Jennings
December 17th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis / Image credit: ©Argus/AdobeStock

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

Sydney Jennings
December 16th 2024
Article

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

© 2024 MJH Life Sciences

All rights reserved.